In vivo, resistance to CDK4/6 and to anti-HER2 treatment inhibitors can be reversed by combination with anti-FGFR drugs, such as lucitanib or erdafitinib [136,184]; this indicates the importance of targeting different pathways in breast cancer (figure 4). This evidence concerns the gene CDK4 and breast carcinoma.